Seeking Alpha

Pozen (POZN -1.1%) gives back the early morning gains it racked up today, after reporting...

Pozen (POZN -1.1%) gives back the early morning gains it racked up today, after reporting positive Phase I testing results of its PA8140-102 drug candidate - a proprietary combination of aspirin and omeprazole, used to treat acid reflux, pectic ulcer and other gastroesophageal problems. It also says that it's successfully manufactured the PA8140 tablet batches, required for the primary NDA stability program. POZN is targeting an NDA submission for the drug no later than the end of April 2013.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector